Strategic Advisory SBN is actively expanding its leadership and scientific advisory base with recent appointments to the Advisory Board and Medical Director roles, signaling openness to strategic partnerships with clinicians and researchers that could facilitate co-development, clinical collaborations, and credibility-building opportunities for market adoption.

Ren.Nu Program The Ren.Nu dietary program, developed with renal dietitians and administered via the non-profit RenAlign, presents a ready-to-market ecosystem for B2B collaborations with healthcare providers, nephrology clinics, and patient organizations to drive referral channels and bundled therapeutic nutrition offerings.

Medical Food Pioneer KetoCitra targets mild to moderate ADPKD, the company’s flagship product, creating a niche, backable use-case for specialty pharmacies, clinics, and patient advocacy groups seeking proven dietary management options aligned with PKD care pathways.

Funding & Growth With early-stage revenue and modest funding, SBN represents a scalable opportunity for strategic investors and channel partners interested in specialty nutraceuticals and CKD/metabolic health, especially given a differentiated product in a high-need market.

Key Market Position Small-company agility coupled with a science-driven focus positions SBN to rapidly form pilot programs, white-label collaborations, and co-marketing arrangements with mid-market nutraceuticals and kidney health brands seeking to broaden their PKD and kidney health portfolios.